A 68 year old woman presented to the clinic with dysuria and urinary frequency. Subsequent physical examinations and laboratory tests revealed a positive urinary tract infection. She has been treated for urinary tract infections 3 times in the past 8 months. The patient asked how to prevent recurrent episodes of urinary tract infections as it significantly decreases her quality of life.
INTRODUCTION
Urinary tract infections (UTI) are commonly found in daily practice. International Urogynecological Association/International Continence Society (2010) defined recurrent urinary tract infections as at least three symptomatic and medically diagnosed UTI in the previous 12 months. The previous UTIs should have resolved prior to a further UTI being diagnosed. 1 Escherichia coli is the main causative pathogen involved in recurrent UTIs, accounting for 80% of infections. 2 Even though the pathogen is the same, risk factors for recurrent UTIs differ in premenopausal and postmenopausal women. In premenopausal women, behaviour risk factors such as frequency of intercourse, use of spermicide, and new sexual partners may increase colonization of E. coli in the vagina and periurethral region. 3, 4 In postmenopausal women, estrogen loss results in thinning of the vaginal epithelium and decreased amounts of glycogen. As a result, amount of lactobacilli decreases and there is an increased risk of colonization with uropathogens. Moreover, associated pathologies such as incontinence, pelvic floor prolapse, and urinary retention increase the risk for recurrent UTI. 5 Various studies have reported the use of antimicrobials and non-antimicrobials such as estrogen and cranberry for preventing recurrence of UTI. In this EBCR we tried to appraise novel studies and guidelines in order to obtain information that may be applied to our case.
CLINICAL QUESTION
The question in the scenario is "In post-menopausal women, what are the effective and applicable methods to reduce the recurrence of urinary tract infections?"
METHODS

Search Strategy
The search was conducted on Pubmed, NEJM, and BMJ on February 8, 2013, using the search tool containing the keywords "recurrent urinary tract infection", "treatment", "prophylaxis", "elderly women", and "postmenopausal". Another search was performed on Google to find organizational or society guidelines on recurrent urinary tract infections. Search results were filtered by the engine according to the following criteria: articles published in the past 5 years, female, human species, and English language. Search strategy, results, and the inclusion and exclusion criteria are shown in a flowchart (Figure 1 ).
Selection
The titles of the filtered results from Pubmed, NEJM, and BMJ were screened using the inclusion criteria. There were no same articles from all three engines. A second screen was conducted by reading the abstracts, and finally 3 articles were useful. Three society guidelines were found on Google, from Society of Obstetricians and Gynaecologists of Canada (SOGC), American College of Obstetricians and Gynecologists (ACOG), and European Association of Urology (EAU). In this report a total of 6 articles were appraised.
Critical Appraisal
Two articles were original researches, one article was a systematic review, and three articles were society guidelines. All were appraised according to the corresponding type of article, comprising of its validity, importancy, and applicability to the patient (Table 1 -2). The checklists used were obtained from www.bmj.com. 
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Obstet Gynecol • Experimental event rate (EER) 37.3% 36.2%
• Relative risk reduction (RRR) -7.5% (increased risk) -15.6% (increased risk)
• Absolute risk reduction (AAR) -25.2% (increased risk) -75.7% (increased risk)
• Number needed to treat (NNT) -4 (harm) -2 (harm)
Applicability
• Can the results help the patient? Yes Yes
• Potential benefit of therapy Yes Yes
• Patient satisfaction -- Table 2 . Critical Appraisal of Systematic Reviews. 
Study/Criteria
RESULTS
Zhong et al conducted a randomised controlled study on 83 postmenopausal women, comparing the effectiveness and safety of patient-initiated single-dose versus continuous low-dose antibiotics. The incidence of urinary tract infections were significantly reduced in both groups, from 5.1 to 1.9 episodes/patient per year (p < 0.001) in the intermittent group, and from 4.7 to 1.4 episodes/patient per year (p < 0.001) in the continuous group. The difference between both groups were not statistically significant. The continuous group had significantly less patients experiencing 0 or 1 episode/ year than the intermittent group (59.4% vs 35.5%, p < 0.05), but it was also associated with significantly higher adverse effects (92.5% vs 63.6%, p < 0.05). 6 McMurdo et al conducted a double-blind, randomised controlled trial with 137 samples. Occurences of UTI in cranberry group and trimethophrim group was 36.2% and 20.6%, respectively. The differences in this proportion was not statistically significant (p 0.084). Withdrawal rate was 9% from the cranberry group and 16% from the trimethoprim group (p = 0.205). 7 Perrotta et al reviewed the effectiveness of estrogens for preventing recurrent UTI in postmenopausal women. Nine articles were reviewed, with three main interventions being conducted: oral estrogens vs placebo, vaginal estrogens vs placebo, and vaginal estrogens vs antibiotics. There was no significant difference in the number of women with UTI in the oral estrogen vs placebo group (RR 1.08, 95%CI 0.88-1.33). In the vaginal estrogen group, both intravaginal estrogen cream (RR 0.25, 95%CI 0.13-0.50) and silicone vaginal ring (RR 0.64, 95%CI 0.47-0.86) significantly reduced the recurrence of UTI. Results in the vaginal estrogen vs antibiotics group were conflicting, one study found less UTI in the antibiotic group (RR 1.30, 95% CI 1.01-1.68) while the other study found less UTI in the estrogen group (RR 0.09, 95% CI 0.02-0.36). 8 SOGC recommended continuous daily antibiotic prophylaxis to prevent recurrent UTI. Post-coital prophylaxis may be used as an alternative in women with recurrent UTI associated with sexual intercourse to minimize cost and side effects. Antibiotics that can be used as prophylaxis are listed in Table 5 . Acute-self treatment should only be restricted to compliant and motivated patients. Vaginal estrogens and cranberry products are also effective. 9 Table 3 . Antimicrobial Prophylaxis for Women with Recurrent Urinary Tract Infections.9
Oral regimens Dose
Continuous prophylaxis
• Cotrimoxazole 1 x 240 mg (daily)
• Nitrofurantoin 1 x 50-100 mg (daily)
• Cephalexin 1 x 125-250 mg (daily)
• Ciprofloxacin 1 x 125 mg (daily)
• EAU recommended non-antimicrobial prophylaxis such as cranberry as a first line of prevention. If unsuccessful, continuous or postcoital antimicrobial prophylaxis should be considered. 10 ACOG recommended to first search for known risk factors associated with recurrence, such as frequent intercourse, long-term spermicide use, diaphragm use, new sexual partner, young age at first UTI, and maternal history of UTI. Similar to other guidelines, prophylaxis can be continuous or postcoital. 11 
COMMENTARY
In general, all appraised articles showed similar methods or recommendations to prevent recurrent UTI.
All three society guidelines satisfied the validity,
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Obstet Gynecol usefulness, and applicability criteria. Recommendations are applicable in daily practice, and all three guidelines support each other. Continuous or postcoital antibiotics to prevent recurrent UTI was recommended in all three guidelines. [9] [10] [11] Zhong et al conducted a very interesting research concerning antimicrobial prophylaxis, comparing continuous or intermittent antibiotic prophylaxis as recommended by all three society guidelines. Predisposing factors used to determine when to begin prophylactic single-dose antibiotic are: working or walking > 2 hours, travelling, emiction holdback, sexual intercourse, diarrhea, and constipation. The authors concluded that patientinitiated intermittent antibiotic use against specific predisposing factors showed similar effectiveness with continuous antibiotic use, but with less gastrointestinal adverse events. 6 Nevertheless, results proved unsignificant statistically may be significant clinically, so we must consider the risk and benefits when choosing mode of antimicrobial prophylaxis. Continuous prophylaxis may be more effective for preventing recurrence of UTI than intermittent prophylaxis, but is associated with more side effects. The weakness in this study is the lack intention-to-treat analysis, as it may affect the results.
McMurdo et al compared the effectiveness of cranberry to trimethoprim. It is a well-conducted study with double-blinding and intention-to-treat analysis. Results could have been more conclusive and applicable if they included another group treated with vaginal estrogens. Cranberry and trimethoprim had no significant differences in terms of reducing UTI and adverse effects. 7 Perrotta et al conducted a systematic review to evaluate the role of estrogens in preventing recurrent UTIs. This review is valid and important, but may not be applied directly as the researches reviewed are few small studies. They concluded that vaginal estrogens are effective, but the type of estrogen to use is less clear. Vaginal creams are cheaper but may be hard to apply for some women as it has to be applied every day. Vaginal rings are expensive and requires a trained doctor to place correctly. Oral estrogens are not effective to prevent recurrent UTIs. 8 
CONCLUSION AND RECOMMENDATIONS
Prevention of recurrent urinary tract infections in postmenopausal women include risk factor identification, non-antimicrobial prophylaxis, and antimicrobial prophylaxis. Consumption of cranberry and usage of vaginal estrogens are effective nonantimicrobial measures. Antimicrobial prophylaxis are divided into continuous single dose daily prophylaxis and intermittent self-initiated prophylaxis. Choice of prophylaxis method depends on the compliance of the patient, as intermittent self-initiated prophylaxis require identification and awareness on when to consume the drug.
In Indonesia, there are limitations in the non-antimicrobial prophylaxis group. Vaginal estrogens are expensive and cranberry are hard to obtain. Therefore, the mode of prevention is suited to the preference of the patient and availability of drugs in that area.
